APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nanotechnology-based Drug Delivery

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nanotechnology-based Drug Delivery Market Outlook and Growth Opportunities 2026

4 March 2026190 pages

Choose your research edition.

Industry ResearchNanotechnology-based Drug Delivery Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Nanotechnology-based Drug Delivery Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Nanotechnology-based Drug Delivery Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nanotechnology-based Drug Delivery Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Nanotechnology-based Drug Delivery Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Nanotechnology-based Drug Delivery market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nanotechnology-based Drug Delivery is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nanotechnology-based Drug Delivery is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nanotechnology-based Drug Delivery is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nanotechnology-based Drug Delivery market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nanotechnology-based Drug Delivery market include AbbVie Inc., BlueWillow Biologics Inc., Camurus AB, Celgene, lnc., Cristal Therapeutics, EyePoint Pharmaceuticals and Johnson and Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Nanotechnology-based Drug Delivery market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nanotechnology-based Drug Delivery and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nanotechnology-based Drug Delivery revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Nanotechnology-based Drug Delivery market.

Nanotechnology-based Drug Delivery Segment by Company

AbbVie Inc.

BlueWillow Biologics Inc.

Camurus AB

Celgene, lnc.

Cristal Therapeutics

EyePoint Pharmaceuticals

Johnson and Johnson

Nanotechnology-based Drug Delivery Segment by Type

Nanocrystals

Nanoparticles

Liposomes

Micelles

Others

Nanotechnology-based Drug Delivery Segment by Application

Hospital

Research Institute

Others

Nanotechnology-based Drug Delivery Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Nanotechnology-based Drug Delivery status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Nanotechnology-based Drug Delivery key companies, revenue, market share, and recent developments.

3. To split the Nanotechnology-based Drug Delivery breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Nanotechnology-based Drug Delivery market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nanotechnology-based Drug Delivery significant trends, drivers, influence factors in global and regions.

6. To analyze Nanotechnology-based Drug Delivery competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nanotechnology-based Drug Delivery market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nanotechnology-based Drug Delivery and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nanotechnology-based Drug Delivery.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nanotechnology-based Drug Delivery industry.

Chapter 3: Detailed analysis of Nanotechnology-based Drug Delivery company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Nanotechnology-based Drug Delivery in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Nanotechnology-based Drug Delivery in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nanotechnology-based Drug Delivery Industry Trends Table 2. Nanotechnology-based Drug Delivery Industry Drivers Table 3. Nanotechnology-based Drug Delivery Industry Opportunities and Challenges Table 4. Nanotechnology-based Drug Delivery Industry Restraints Table 5. Global Nanotechnology-based Drug Delivery Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nanotechnology-based Drug Delivery Revenue Share by Company (2021-2026) Table 7. Global Nanotechnology-based Drug Delivery Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Nanotechnology-based Drug Delivery Key Company Manufacturing Base & Headquarters Table 9. Global Nanotechnology-based Drug Delivery Company, Product Type & Application Table 10. Global Nanotechnology-based Drug Delivery Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Nanotechnology-based Drug Delivery by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Nanocrystals Table 15. Significant Companies of Nanoparticles Table 16. Significant Companies of Liposomes Table 17. Significant Companies of Micelles Table 18. Significant Companies of Others Table 19. Global Nanotechnology-based Drug Delivery Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Nanotechnology-based Drug Delivery Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Nanotechnology-based Drug Delivery Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Nanotechnology-based Drug Delivery Sales Value Share by Type (2021-2026) Table 23. Global Nanotechnology-based Drug Delivery Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Table 25. Significant Companies of Research Institute Table 26. Significant Companies of Others Table 27. Global Nanotechnology-based Drug Delivery Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Nanotechnology-based Drug Delivery Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Nanotechnology-based Drug Delivery Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Nanotechnology-based Drug Delivery Sales Value Share by Application (2021-2026) Table 31. Global Nanotechnology-based Drug Delivery Sales Value Share by Application (2027-2032) Table 32. Global Nanotechnology-based Drug Delivery Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Nanotechnology-based Drug Delivery Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Nanotechnology-based Drug Delivery Sales Value Share by Region (2021-2026) Table 35. Global Nanotechnology-based Drug Delivery Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Nanotechnology-based Drug Delivery Sales Value Share by Region (2027-2032) Table 37. Global Nanotechnology-based Drug Delivery Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Nanotechnology-based Drug Delivery Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Nanotechnology-based Drug Delivery Sales Value Market Share by Country (2021-2026) Table 40. Global Nanotechnology-based Drug Delivery Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Nanotechnology-based Drug Delivery Sales Value Market Share by Country (2027-2032) Table 42. AbbVie Inc. Company Information Table 43. AbbVie Inc. Business Overview Table 44. AbbVie Inc. Nanotechnology-based Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. AbbVie Inc. Nanotechnology-based Drug Delivery Product Portfolio Table 46. AbbVie Inc. Recent Development Table 47. BlueWillow Biologics Inc. Company Information Table 48. BlueWillow Biologics Inc. Business Overview Table 49. BlueWillow Biologics Inc. Nanotechnology-based Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. BlueWillow Biologics Inc. Nanotechnology-based Drug Delivery Product Portfolio Table 51. BlueWillow Biologics Inc. Recent Development Table 52. Camurus AB Company Information Table 53. Camurus AB Business Overview Table 54. Camurus AB Nanotechnology-based Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Camurus AB Nanotechnology-based Drug Delivery Product Portfolio Table 56. Camurus AB Recent Development Table 57. Celgene, lnc. Company Information Table 58. Celgene, lnc. Business Overview Table 59. Celgene, lnc. Nanotechnology-based Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Celgene, lnc. Nanotechnology-based Drug Delivery Product Portfolio Table 61. Celgene, lnc. Recent Development Table 62. Cristal Therapeutics Company Information Table 63. Cristal Therapeutics Business Overview Table 64. Cristal Therapeutics Nanotechnology-based Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Cristal Therapeutics Nanotechnology-based Drug Delivery Product Portfolio Table 66. Cristal Therapeutics Recent Development Table 67. EyePoint Pharmaceuticals Company Information Table 68. EyePoint Pharmaceuticals Business Overview Table 69. EyePoint Pharmaceuticals Nanotechnology-based Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. EyePoint Pharmaceuticals Nanotechnology-based Drug Delivery Product Portfolio Table 71. EyePoint Pharmaceuticals Recent Development Table 72. Johnson and Johnson Company Information Table 73. Johnson and Johnson Business Overview Table 74. Johnson and Johnson Nanotechnology-based Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Johnson and Johnson Nanotechnology-based Drug Delivery Product Portfolio Table 76. Johnson and Johnson Recent Development Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. Nanotechnology-based Drug Delivery Product Image Figure 2. Global Nanotechnology-based Drug Delivery Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nanotechnology-based Drug Delivery Market Size (2021-2032) & (US$ Million) Figure 4. Global Nanotechnology-based Drug Delivery Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Nanocrystals Image Figure 8. Nanoparticles Image Figure 9. Liposomes Image Figure 10. Micelles Image Figure 11. Others Image Figure 12. Global Nanotechnology-based Drug Delivery Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Nanotechnology-based Drug Delivery Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Nanotechnology-based Drug Delivery Sales Value Share by Type (2021-2032) Figure 15. Hospital Image Figure 16. Research Institute Image Figure 17. Others Image Figure 18. Global Nanotechnology-based Drug Delivery Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Nanotechnology-based Drug Delivery Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Nanotechnology-based Drug Delivery Sales Value Share by Application (2021-2032) Figure 21. Global Nanotechnology-based Drug Delivery Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Nanotechnology-based Drug Delivery Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Nanotechnology-based Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 24. North America Nanotechnology-based Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Nanotechnology-based Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Nanotechnology-based Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Nanotechnology-based Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Nanotechnology-based Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Nanotechnology-based Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 30. South America Nanotechnology-based Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Nanotechnology-based Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Nanotechnology-based Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Nanocrystals
  • Nanoparticles
  • Liposomes
  • Micelles
  • Others
Applications
  • Hospital
  • Research Institute
  • Others
Companies covered
  • AbbVie Inc.
  • BlueWillow Biologics Inc.
  • Camurus AB
  • Celgene, lnc.
  • Cristal Therapeutics
  • EyePoint Pharmaceuticals
  • Johnson and Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nanotechnology-based Drug Delivery Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nanotechnology-based Drug Delivery Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Nanotechnology-based Drug Delivery Market Dynamics
  1. 2.1 Nanotechnology-based Drug Delivery Industry Trends
  2. 2.2 Nanotechnology-based Drug Delivery Industry Drivers
  3. 2.3 Nanotechnology-based Drug Delivery Industry Opportunities and Challenges
  4. 2.4 Nanotechnology-based Drug Delivery Industry Restraints
3 Nanotechnology-based Drug Delivery Market by Company
  1. 3.1 Global Nanotechnology-based Drug Delivery Company Revenue Ranking in 2025
  2. 3.2 Global Nanotechnology-based Drug Delivery Revenue by Company (2021-2026)
  3. 3.3 Global Nanotechnology-based Drug Delivery Company Ranking (2024-2026)
  4. 3.4 Global Nanotechnology-based Drug Delivery Company Manufacturing Base and Headquarters
  5. 3.5 Global Nanotechnology-based Drug Delivery Company Product Type and Application
  6. 3.6 Global Nanotechnology-based Drug Delivery Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Nanotechnology-based Drug Delivery Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Nanotechnology-based Drug Delivery Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Nanotechnology-based Drug Delivery Market by Type
  1. 4.1 Nanotechnology-based Drug Delivery Type Introduction
  2. 4.1.1 Nanocrystals
  3. 4.1.2 Nanoparticles
  4. 4.1.3 Liposomes
  5. 4.1.4 Micelles
  6. 4.1.5 Others
  7. 4.2 Global Nanotechnology-based Drug Delivery Sales Value by Type
  8. 4.2.1 Global Nanotechnology-based Drug Delivery Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Nanotechnology-based Drug Delivery Sales Value by Type (2021-2032)
  10. 4.2.3 Global Nanotechnology-based Drug Delivery Sales Value Share by Type (2021-2032)
5 Nanotechnology-based Drug Delivery Market by Application
  1. 5.1 Nanotechnology-based Drug Delivery Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Research Institute
  4. 5.1.3 Others
  5. 5.2 Global Nanotechnology-based Drug Delivery Sales Value by Application
  6. 5.2.1 Global Nanotechnology-based Drug Delivery Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nanotechnology-based Drug Delivery Sales Value by Application (2021-2032)
  8. 5.2.3 Global Nanotechnology-based Drug Delivery Sales Value Share by Application (2021-2032)
6 Nanotechnology-based Drug Delivery Regional Value Analysis
  1. 6.1 Global Nanotechnology-based Drug Delivery Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nanotechnology-based Drug Delivery Sales Value by Region (2021-2032)
  3. 6.2.1 Global Nanotechnology-based Drug Delivery Sales Value by Region: 2021-2026
  4. 6.2.2 Global Nanotechnology-based Drug Delivery Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nanotechnology-based Drug Delivery Sales Value (2021-2032)
  7. 6.3.2 North America Nanotechnology-based Drug Delivery Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Nanotechnology-based Drug Delivery Sales Value (2021-2032)
  10. 6.4.2 Europe Nanotechnology-based Drug Delivery Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Nanotechnology-based Drug Delivery Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Nanotechnology-based Drug Delivery Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Nanotechnology-based Drug Delivery Sales Value (2021-2032)
  16. 6.6.2 South America Nanotechnology-based Drug Delivery Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Nanotechnology-based Drug Delivery Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Nanotechnology-based Drug Delivery Sales Value Share by Country, 2025 VS 2032
7 Nanotechnology-based Drug Delivery Country-level Value Analysis
  1. 7.1 Global Nanotechnology-based Drug Delivery Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nanotechnology-based Drug Delivery Sales Value by Country (2021-2032)
  3. 7.2.1 Global Nanotechnology-based Drug Delivery Sales Value by Country (2021-2026)
  4. 7.2.2 Global Nanotechnology-based Drug Delivery Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Nanotechnology-based Drug Delivery Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Nanotechnology-based Drug Delivery Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Nanotechnology-based Drug Delivery Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AbbVie Inc.
  2. 8.1.1 AbbVie Inc. Company Information
  3. 8.1.2 AbbVie Inc. Business Overview
  4. 8.1.3 AbbVie Inc. Nanotechnology-based Drug Delivery Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AbbVie Inc. Nanotechnology-based Drug Delivery Product Portfolio
  6. 8.1.5 AbbVie Inc. Recent Developments
  7. 8.2 BlueWillow Biologics Inc.
  8. 8.2.1 BlueWillow Biologics Inc. Company Information
  9. 8.2.2 BlueWillow Biologics Inc. Business Overview
  10. 8.2.3 BlueWillow Biologics Inc. Nanotechnology-based Drug Delivery Revenue and Gross Margin (2021-2026)
  11. 8.2.4 BlueWillow Biologics Inc. Nanotechnology-based Drug Delivery Product Portfolio
  12. 8.2.5 BlueWillow Biologics Inc. Recent Developments
  13. 8.3 Camurus AB
  14. 8.3.1 Camurus AB Company Information
  15. 8.3.2 Camurus AB Business Overview
  16. 8.3.3 Camurus AB Nanotechnology-based Drug Delivery Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Camurus AB Nanotechnology-based Drug Delivery Product Portfolio
  18. 8.3.5 Camurus AB Recent Developments
  19. 8.4 Celgene, lnc.
  20. 8.4.1 Celgene, lnc. Company Information
  21. 8.4.2 Celgene, lnc. Business Overview
  22. 8.4.3 Celgene, lnc. Nanotechnology-based Drug Delivery Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Celgene, lnc. Nanotechnology-based Drug Delivery Product Portfolio
  24. 8.4.5 Celgene, lnc. Recent Developments
  25. 8.5 Cristal Therapeutics
  26. 8.5.1 Cristal Therapeutics Company Information
  27. 8.5.2 Cristal Therapeutics Business Overview
  28. 8.5.3 Cristal Therapeutics Nanotechnology-based Drug Delivery Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Cristal Therapeutics Nanotechnology-based Drug Delivery Product Portfolio
  30. 8.5.5 Cristal Therapeutics Recent Developments
  31. 8.6 EyePoint Pharmaceuticals
  32. 8.6.1 EyePoint Pharmaceuticals Company Information
  33. 8.6.2 EyePoint Pharmaceuticals Business Overview
  34. 8.6.3 EyePoint Pharmaceuticals Nanotechnology-based Drug Delivery Revenue and Gross Margin (2021-2026)
  35. 8.6.4 EyePoint Pharmaceuticals Nanotechnology-based Drug Delivery Product Portfolio
  36. 8.6.5 EyePoint Pharmaceuticals Recent Developments
  37. 8.7 Johnson and Johnson
  38. 8.7.1 Johnson and Johnson Company Information
  39. 8.7.2 Johnson and Johnson Business Overview
  40. 8.7.3 Johnson and Johnson Nanotechnology-based Drug Delivery Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Johnson and Johnson Nanotechnology-based Drug Delivery Product Portfolio
  42. 8.7.5 Johnson and Johnson Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst